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-Acetylcysteine Somewhere
etween Scylla and Charybdis
hiele et al. (1) report a study dealing with the impact of
-acetylcysteine (NAC) administered simultaneously on prevent-
ng iodinated contrast agent-induced nephropathy and reperfusion
njury in patients with ST-segment elevation myocardial infarction
reated by percutaneous coronary intervention (PCI). The study
ncluded 126 patients compared with a placebo-treated group.
heir results as well as conclusions generate many noteworthy
ssociations.
Free oxygen radicals are regarded as variable typically involved
ither in reperfusion of previously ischemic tissue anywhere in the
ody or in specific interaction between the iodinated contrast agent
nd the filtration capacity of the kidney, with the latter being most
ronounced with previous kidney injury.
As a result, the exact mode of action of NAC (defense against
ree oxygen radicals) in the LIPSIA-N-ACC (Prospective, single-
lind, placebo-controlled, randomized Leipzig Immediate Percu-
aneouS coronary Intervention Acute myocardial infarction
-ACC) trial still remains unclear. First, most importantly, it
hould be taken into account that all patients had normal serum
reatinine level, perhaps a crucial fact for further evaluation. A
ifferent study design including patients with a priori elevated
erum creatinine levels (roughly at least 140 mol/l) would be
ore appropriately representative by making the same size of the
atient group sufficient for final statistical analysis. Even so, the
ncidence of contrast agent-induced nephropathy incidence in
he NAC-treated arm of the LIPSIA-N-ACC trial was reported
o be lower by 6% when compared with the placebo group. Second,
nother fact raising some doubt is the selected dose of NAC: 1,200
g of NAC before PCI cannot be regarded as a high dose even if
dministered intravenously. In experimental studies, an approxi-
ate dose of 100 mg NAC/kg body weight has been used before
nduction of injury (i.e., this is de facto the total dose of NAC used
n the present trial including doses administered within 48 h
ost-procedurally). Third, likewise, the distribution of NAC
etween the 2 target organs remains unclear: the kidney exposed to
he burden of the iodinated contrast agent versus the ischemic/
eperfused myocardium (i.e., the proportion of NAC entering the
aforementioned organs and even more so, after recirculation
hrough the pulmonary vessel bed: a Killip class 2 was reported
n 11% of the NAC group and in 14% of the placebo group). The
AC bolus and, actually, the whole dose administered is figura-
ively somewhere between Scylla and Charybdis, with the former
eing nephron stress and the latter ischemic and reperfusion
yocardial injury. Fourth, the enigma for researchers to be yet
esolved continues to be which “high” dose of NAC is actually
high” in terms of being functionally adequate for both the organ iompartments in question. The authors (1) report a 20%
eduction of oxidative stress markers in the NAC group: this is,
owever, a biochemical parameter, perhaps not yet reaching a
evel high enough to have a functional or possibly structural
mpact on the injured myocardial area. Fortunately enough,
lmost all patients were receiving angiotensin-converting en-
yme inhibitors/angiotensin II type 1 antagonists and statins—
opefully comparable?—in both study groups. Fifth, earlier
uman studies (for details, see appropriate references in Thiele
t al. [1]) used different types of myocardial reperfusion/
oronary artery recanalization: fibrinolysis (2) involving opening
f the artery by gradual dissolution of a fresh red thrombus,
hereas current PCI is “an instantaneous switch for coronary
lood flow from the closed to open position.” Sixth, the
forementioned makes it unclear whether mode NAC action on
he myocardial microvasculature is the same in both reperfusion
echniques. Finally, judging by experimental animal studies,
AC seems to exert more beneficial effects on the filtration
apacity of the kidney in its more developed injury (3).
The reader could now perhaps say the study simply failed.
owever, from a scientific point of view, I personally feel this
ell-designed study has provided many provoking stimuli for
urther research and definitely is not to be perceived as a breaking
oint for making indiscriminate decisions in our current clinical
ractice.
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eply
e thank Prof. Sochman for his interest in our paper (1) and agree
hat the exact mode of action of N-acetylcysteine (NAC) for the
efense against free oxygen radicals—as shown in our LIPSIA-N-
CC (Prospective, single-blind, placebo-controlled, randomized
eipzig Immediate PercutaneouS coronary Intervention Acute
yocardial infarction N-ACC) trial—remains unclear. However,n contrast to the first of 7 statements by Prof. Sochman, not all
